| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Echocardiography, Three-Dimensional | 53 | 2024 | 516 | 11.340 |
Why?
|
| Heart Ventricles | 48 | 2024 | 760 | 7.410 |
Why?
|
| Echocardiography | 54 | 2023 | 911 | 6.500 |
Why?
|
| Tricuspid Valve Insufficiency | 17 | 2023 | 111 | 5.670 |
Why?
|
| Ventricular Function, Right | 22 | 2024 | 142 | 4.580 |
Why?
|
| Ventricular Function, Left | 31 | 2023 | 592 | 4.280 |
Why?
|
| Tricuspid Valve | 15 | 2023 | 96 | 3.630 |
Why?
|
| Ventricular Dysfunction, Right | 10 | 2024 | 134 | 2.730 |
Why?
|
| Heart Atria | 13 | 2022 | 250 | 2.450 |
Why?
|
| Stroke Volume | 26 | 2024 | 456 | 2.300 |
Why?
|
| Ventricular Dysfunction, Left | 10 | 2023 | 318 | 2.220 |
Why?
|
| Atrial Function, Left | 8 | 2021 | 46 | 2.000 |
Why?
|
| Heart Failure | 11 | 2023 | 1204 | 1.990 |
Why?
|
| Amyloidosis | 10 | 2024 | 115 | 1.890 |
Why?
|
| Ventricular Remodeling | 7 | 2022 | 96 | 1.820 |
Why?
|
| Mitral Valve Insufficiency | 6 | 2024 | 187 | 1.820 |
Why?
|
| Hypertension, Pulmonary | 6 | 2018 | 346 | 1.740 |
Why?
|
| Echocardiography, Transesophageal | 12 | 2022 | 344 | 1.730 |
Why?
|
| Defibrillators, Implantable | 6 | 2021 | 129 | 1.700 |
Why?
|
| Reproducibility of Results | 36 | 2023 | 2705 | 1.500 |
Why?
|
| Predictive Value of Tests | 28 | 2023 | 1673 | 1.490 |
Why?
|
| Image Interpretation, Computer-Assisted | 14 | 2020 | 663 | 1.400 |
Why?
|
| Cardiac Volume | 4 | 2017 | 53 | 1.400 |
Why?
|
| Humans | 130 | 2024 | 86643 | 1.380 |
Why?
|
| Reference Values | 18 | 2023 | 674 | 1.350 |
Why?
|
| Magnetic Resonance Imaging, Cine | 11 | 2023 | 159 | 1.330 |
Why?
|
| Hemodynamics | 6 | 2019 | 710 | 1.330 |
Why?
|
| Echocardiography, Doppler | 9 | 2020 | 187 | 1.250 |
Why?
|
| Atrial Fibrillation | 3 | 2022 | 288 | 1.240 |
Why?
|
| Male | 85 | 2024 | 40965 | 1.220 |
Why?
|
| Middle Aged | 62 | 2023 | 25028 | 1.180 |
Why?
|
| Female | 85 | 2024 | 44532 | 1.150 |
Why?
|
| Diastole | 10 | 2021 | 144 | 1.130 |
Why?
|
| Heart Diseases | 8 | 2021 | 290 | 1.120 |
Why?
|
| Heart-Assist Devices | 6 | 2021 | 731 | 1.110 |
Why?
|
| Pulmonary Embolism | 3 | 2023 | 222 | 0.990 |
Why?
|
| Pacemaker, Artificial | 4 | 2019 | 87 | 0.990 |
Why?
|
| Thrombophilia | 1 | 2023 | 22 | 0.940 |
Why?
|
| Aged | 45 | 2024 | 18415 | 0.940 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2023 | 10 | 0.920 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2018 | 1204 | 0.890 |
Why?
|
| Atrial Remodeling | 2 | 2022 | 17 | 0.890 |
Why?
|
| Echocardiography, Doppler, Color | 7 | 2022 | 103 | 0.890 |
Why?
|
| Myocardial Contraction | 3 | 2018 | 244 | 0.870 |
Why?
|
| Healthy Volunteers | 8 | 2022 | 143 | 0.860 |
Why?
|
| Adult | 43 | 2024 | 25648 | 0.840 |
Why?
|
| Heart | 6 | 2023 | 539 | 0.820 |
Why?
|
| Atrial Function, Right | 4 | 2020 | 12 | 0.800 |
Why?
|
| Cardiac Imaging Techniques | 3 | 2020 | 25 | 0.800 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2020 | 462 | 0.770 |
Why?
|
| Thrombosis | 1 | 2023 | 296 | 0.760 |
Why?
|
| Heart Defects, Congenital | 2 | 2014 | 351 | 0.760 |
Why?
|
| Aorta, Thoracic | 2 | 2019 | 165 | 0.750 |
Why?
|
| Cardiomyopathies | 5 | 2023 | 240 | 0.710 |
Why?
|
| Aortic Valve | 5 | 2023 | 222 | 0.690 |
Why?
|
| Aortic Valve Stenosis | 5 | 2023 | 131 | 0.690 |
Why?
|
| Observer Variation | 8 | 2023 | 602 | 0.680 |
Why?
|
| Contrast Media | 5 | 2023 | 1078 | 0.660 |
Why?
|
| Vascular Calcification | 1 | 2019 | 39 | 0.650 |
Why?
|
| Trastuzumab | 2 | 2016 | 68 | 0.650 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 162 | 0.650 |
Why?
|
| Hemothorax | 1 | 2018 | 15 | 0.650 |
Why?
|
| Heart Massage | 1 | 2018 | 12 | 0.640 |
Why?
|
| Aortic Diseases | 1 | 2019 | 100 | 0.640 |
Why?
|
| Mitral Valve | 7 | 2022 | 248 | 0.640 |
Why?
|
| Ventricular Fibrillation | 1 | 2018 | 65 | 0.630 |
Why?
|
| Early Diagnosis | 1 | 2018 | 131 | 0.610 |
Why?
|
| Prospective Studies | 20 | 2021 | 4213 | 0.580 |
Why?
|
| Holography | 1 | 2016 | 4 | 0.580 |
Why?
|
| Severity of Illness Index | 13 | 2022 | 1801 | 0.560 |
Why?
|
| Sensitivity and Specificity | 12 | 2017 | 1991 | 0.550 |
Why?
|
| Atherosclerosis | 1 | 2018 | 244 | 0.530 |
Why?
|
| Anticoagulants | 2 | 2018 | 408 | 0.530 |
Why?
|
| Anthracyclines | 1 | 2015 | 37 | 0.520 |
Why?
|
| Retrospective Studies | 23 | 2024 | 8489 | 0.520 |
Why?
|
| Pulmonary Valve | 1 | 2015 | 32 | 0.510 |
Why?
|
| Taxoids | 1 | 2015 | 129 | 0.510 |
Why?
|
| Sex Factors | 5 | 2018 | 1054 | 0.500 |
Why?
|
| Heart Arrest | 1 | 2018 | 265 | 0.500 |
Why?
|
| Echocardiography, Doppler, Pulsed | 3 | 2019 | 23 | 0.490 |
Why?
|
| Electrodes, Implanted | 2 | 2014 | 171 | 0.490 |
Why?
|
| Veins | 1 | 2014 | 94 | 0.480 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2013 | 24 | 0.480 |
Why?
|
| Mitral Valve Prolapse | 1 | 2013 | 22 | 0.470 |
Why?
|
| Organometallic Compounds | 1 | 2014 | 132 | 0.470 |
Why?
|
| Algorithms | 5 | 2017 | 1830 | 0.460 |
Why?
|
| Cardiac Catheterization | 4 | 2019 | 291 | 0.460 |
Why?
|
| Aged, 80 and over | 16 | 2023 | 6509 | 0.460 |
Why?
|
| Machine Learning | 3 | 2020 | 232 | 0.460 |
Why?
|
| Sample Size | 1 | 2013 | 130 | 0.460 |
Why?
|
| Decision Making | 1 | 2018 | 642 | 0.450 |
Why?
|
| Image Enhancement | 8 | 2019 | 563 | 0.440 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 2 | 2023 | 14 | 0.440 |
Why?
|
| Prognosis | 13 | 2020 | 3679 | 0.430 |
Why?
|
| Ventricular Pressure | 3 | 2018 | 34 | 0.430 |
Why?
|
| Quality Improvement | 1 | 2016 | 428 | 0.420 |
Why?
|
| Terminology as Topic | 1 | 2013 | 217 | 0.420 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2023 | 3362 | 0.410 |
Why?
|
| Health Care Costs | 1 | 2013 | 238 | 0.410 |
Why?
|
| Sarcoidosis | 3 | 2016 | 71 | 0.390 |
Why?
|
| Transillumination | 2 | 2021 | 9 | 0.380 |
Why?
|
| Takotsubo Cardiomyopathy | 2 | 2022 | 9 | 0.360 |
Why?
|
| Models, Statistical | 1 | 2013 | 574 | 0.360 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 469 | 0.350 |
Why?
|
| Systole | 3 | 2018 | 129 | 0.350 |
Why?
|
| Age Factors | 4 | 2018 | 1851 | 0.350 |
Why?
|
| Atrial Appendage | 2 | 2021 | 26 | 0.340 |
Why?
|
| Antihypertensive Agents | 1 | 2013 | 521 | 0.340 |
Why?
|
| Heart Valve Diseases | 2 | 2024 | 109 | 0.330 |
Why?
|
| Linear Models | 3 | 2018 | 421 | 0.320 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 999 | 0.310 |
Why?
|
| Young Adult | 11 | 2022 | 5976 | 0.300 |
Why?
|
| Prosthesis Design | 2 | 2019 | 278 | 0.300 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2016 | 59 | 0.280 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 1565 | 0.270 |
Why?
|
| Pandemics | 2 | 2021 | 740 | 0.260 |
Why?
|
| Aorta | 3 | 2021 | 280 | 0.260 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 2903 | 0.250 |
Why?
|
| Software | 3 | 2022 | 654 | 0.250 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2020 | 579 | 0.240 |
Why?
|
| Italy | 3 | 2019 | 106 | 0.240 |
Why?
|
| Cohort Studies | 5 | 2018 | 2767 | 0.230 |
Why?
|
| Multimodal Imaging | 3 | 2023 | 110 | 0.220 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2023 | 318 | 0.220 |
Why?
|
| Europe | 3 | 2021 | 309 | 0.220 |
Why?
|
| Electric Countershock | 1 | 2022 | 47 | 0.210 |
Why?
|
| Follow-Up Studies | 8 | 2021 | 3640 | 0.200 |
Why?
|
| Risk Factors | 5 | 2019 | 5417 | 0.200 |
Why?
|
| Organ Size | 3 | 2019 | 364 | 0.200 |
Why?
|
| Endocarditis | 1 | 2021 | 18 | 0.200 |
Why?
|
| Treatment Outcome | 6 | 2022 | 7993 | 0.200 |
Why?
|
| Stress, Mechanical | 3 | 2016 | 248 | 0.200 |
Why?
|
| Comorbidity | 3 | 2021 | 943 | 0.190 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2022 | 73 | 0.190 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 93 | 0.190 |
Why?
|
| Survival Analysis | 4 | 2018 | 1538 | 0.190 |
Why?
|
| Virtual Reality | 1 | 2020 | 21 | 0.190 |
Why?
|
| Pulmonary Artery | 2 | 2019 | 306 | 0.180 |
Why?
|
| Aminobutyrates | 1 | 2019 | 13 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1036 | 0.180 |
Why?
|
| Vascular Stiffness | 1 | 2019 | 26 | 0.180 |
Why?
|
| Protease Inhibitors | 1 | 2019 | 72 | 0.180 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2019 | 166 | 0.180 |
Why?
|
| Vasodilation | 1 | 2019 | 96 | 0.180 |
Why?
|
| Tetrazoles | 1 | 2019 | 50 | 0.170 |
Why?
|
| Time Factors | 6 | 2019 | 5210 | 0.170 |
Why?
|
| Chicago | 3 | 2019 | 1379 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2020 | 2601 | 0.170 |
Why?
|
| Gadolinium | 2 | 2023 | 103 | 0.170 |
Why?
|
| Septal Occluder Device | 1 | 2019 | 42 | 0.170 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2019 | 67 | 0.170 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 90 | 0.170 |
Why?
|
| Forecasting | 2 | 2018 | 304 | 0.170 |
Why?
|
| Diuretics | 1 | 2019 | 124 | 0.170 |
Why?
|
| Cicatrix | 1 | 2019 | 63 | 0.170 |
Why?
|
| Quebec | 2 | 2015 | 11 | 0.160 |
Why?
|
| Ultrasonography | 1 | 2020 | 695 | 0.160 |
Why?
|
| Dilatation | 1 | 2018 | 48 | 0.160 |
Why?
|
| Feasibility Studies | 5 | 2019 | 751 | 0.160 |
Why?
|
| Tachycardia, Ventricular | 1 | 2019 | 115 | 0.160 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 307 | 0.160 |
Why?
|
| Reference Standards | 1 | 2018 | 159 | 0.150 |
Why?
|
| Device Removal | 1 | 2019 | 161 | 0.150 |
Why?
|
| Body Size | 1 | 2017 | 91 | 0.150 |
Why?
|
| Coronary Stenosis | 1 | 2016 | 39 | 0.140 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2017 | 47 | 0.140 |
Why?
|
| Adolescent | 7 | 2022 | 8981 | 0.140 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1996 | 41 | 0.140 |
Why?
|
| Radiation Protection | 1 | 2016 | 25 | 0.140 |
Why?
|
| Myocardium | 1 | 2019 | 529 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 827 | 0.140 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2015 | 33 | 0.140 |
Why?
|
| Societies, Medical | 1 | 2019 | 572 | 0.140 |
Why?
|
| Phenotype | 1 | 2022 | 2378 | 0.140 |
Why?
|
| Radionuclide Imaging | 1 | 2016 | 220 | 0.130 |
Why?
|
| Coronary Vessels | 1 | 2016 | 177 | 0.130 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2015 | 64 | 0.130 |
Why?
|
| Emergency Medical Services | 1 | 2018 | 209 | 0.130 |
Why?
|
| Chordae Tendineae | 1 | 2015 | 23 | 0.130 |
Why?
|
| Case-Control Studies | 2 | 2019 | 1805 | 0.130 |
Why?
|
| Biomechanical Phenomena | 1 | 2016 | 457 | 0.120 |
Why?
|
| Flow Cytometry | 1 | 1996 | 679 | 0.120 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 1621 | 0.120 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2013 | 60 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 268 | 0.120 |
Why?
|
| Heart Block | 1 | 2013 | 32 | 0.120 |
Why?
|
| Cost Savings | 1 | 2013 | 66 | 0.120 |
Why?
|
| Models, Economic | 1 | 2013 | 60 | 0.120 |
Why?
|
| Color | 1 | 2013 | 81 | 0.120 |
Why?
|
| Iatrogenic Disease | 1 | 2013 | 69 | 0.110 |
Why?
|
| Disease Management | 1 | 2015 | 327 | 0.110 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 187 | 0.110 |
Why?
|
| Tertiary Care Centers | 1 | 2012 | 94 | 0.110 |
Why?
|
| Workflow | 2 | 2023 | 77 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 894 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2017 | 751 | 0.100 |
Why?
|
| Population Surveillance | 1 | 2012 | 219 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 454 | 0.100 |
Why?
|
| ROC Curve | 3 | 2018 | 752 | 0.100 |
Why?
|
| Survival Rate | 3 | 2021 | 1863 | 0.090 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 298 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 1996 | 1376 | 0.090 |
Why?
|
| Computer Simulation | 1 | 2013 | 1078 | 0.080 |
Why?
|
| Prevalence | 2 | 2024 | 1239 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2501 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2017 | 2261 | 0.080 |
Why?
|
| Elastic Modulus | 2 | 2016 | 36 | 0.070 |
Why?
|
| Electrocardiography | 2 | 2021 | 478 | 0.070 |
Why?
|
| Cause of Death | 2 | 2017 | 277 | 0.070 |
Why?
|
| Education, Medical, Continuing | 2 | 2016 | 107 | 0.060 |
Why?
|
| Cardiology | 2 | 2016 | 123 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2016 | 912 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 159 | 0.060 |
Why?
|
| Radiology | 2 | 2016 | 194 | 0.060 |
Why?
|
| Prealbumin | 1 | 2023 | 34 | 0.060 |
Why?
|
| Brazil | 1 | 2023 | 69 | 0.060 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2023 | 86 | 0.060 |
Why?
|
| Ultrasonography, Doppler | 1 | 2023 | 80 | 0.060 |
Why?
|
| United States | 3 | 2019 | 6672 | 0.050 |
Why?
|
| Disease Progression | 2 | 2016 | 1531 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2021 | 156 | 0.050 |
Why?
|
| Abscess | 1 | 2021 | 91 | 0.050 |
Why?
|
| Random Allocation | 1 | 2020 | 332 | 0.050 |
Why?
|
| Blood Flow Velocity | 1 | 2020 | 197 | 0.050 |
Why?
|
| Valsartan | 1 | 2019 | 20 | 0.050 |
Why?
|
| Neprilysin | 1 | 2019 | 42 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2019 | 54 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 68 | 0.040 |
Why?
|
| Arterial Pressure | 1 | 2019 | 38 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 224 | 0.040 |
Why?
|
| Aging | 1 | 2024 | 691 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2019 | 119 | 0.040 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2019 | 108 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 349 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 294 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2018 | 71 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 329 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 257 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2018 | 150 | 0.040 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 16 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1019 | 0.040 |
Why?
|
| Hypertonic Solutions | 1 | 1996 | 17 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 814 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 334 | 0.030 |
Why?
|
| Culture Media | 1 | 1996 | 147 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2016 | 121 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2016 | 232 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 2015 | 274 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2016 | 227 | 0.030 |
Why?
|
| Animals | 1 | 2014 | 26582 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 164 | 0.030 |
Why?
|
| Automation | 1 | 2015 | 106 | 0.030 |
Why?
|
| Stomach | 1 | 2015 | 108 | 0.030 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2014 | 19 | 0.030 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2014 | 27 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1996 | 1041 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2016 | 262 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 839 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 860 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 859 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2012 | 86 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 229 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 702 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 1163 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 1577 | 0.030 |
Why?
|
| Robotic Surgical Procedures | 1 | 2015 | 267 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2012 | 705 | 0.020 |
Why?
|
| Stroke | 1 | 2014 | 965 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2360 | 0.020 |
Why?
|